Clinical Trials Logo

Gastrointestinal Disease clinical trials

View clinical trials related to Gastrointestinal Disease.

Filter by:

NCT ID: NCT00101725 Completed - Clinical trials for Irritable Bowel Syndrome

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

Start date: December 2004
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).

NCT ID: NCT00073047 Completed - Ulcerative Colitis Clinical Trials

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. Participants in the study will have a number of visits to a research center over a five-month period. All study related care and medication is provided to qualified participants at no cost: this includes all visits, examinations, and laboratory work.

NCT ID: NCT00072943 Completed - Crohn's Disease Clinical Trials

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

Start date: March 2002
Phase: Phase 2
Study type: Interventional

The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD). HuZAF is a humanized anti-Interferon-gamma (anti-IFN-γ) monoclonal antibody, which binds and blocks IFN-γ, a protein in the immune system that is involved in inflammation. Antibodies are proteins normally produced by our immune system to help fight off foreign substances. Scientists have been able to make therapeutic humanized monoclonal antibodies, similar to the antibodies in our bodies, to target diseases.